| Abstract | Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies. |
| Authors | Klaus Bendtzen, Pierre Geborek, Morten Svenson, Lotta Larsson, Meliha C Kapetanovic, Tore Saxne
(Affiliation: Rigshospitalet, Institut for Inflammationsforskning (IIR), BioMonitor ApS, Symbion. kben at mail.dk)
|
| Journal | Ugeskrift for laeger
(Ugeskr Laeger)
Vol. 169
Issue 5
Pg. 420-3
(Jan 29 2007)
ISSN: 1603-6824 Denmark |
| Vernacular Title | Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation. |
| PMID | 17280636
(Publication Type: English Abstract, Journal Article)
|
